Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$224.84
-$4.62(-2.38%)
At close: 4:00 PM EDT
$224.84
-$4.62(-2.38%)
Day’s Range― - ―
52-Week Range$106.12 - $309.35
Previous Close$186.33
Volume1.74M
Average Volume (3M)3.61M
Market Cap
$35.63B
Enterprise Value$42.56B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$2.23B
Price to Earnings (P/E)40.1
Beta1.15
Next Earnings
Feb 11, 2027EPS Estimate
1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.89
Shares Outstanding151,000,000
10 Day Avg. Volume2,007,427
30 Day Avg. Volume3,606,521
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue9.38
Enterprise Value/Gross Profit13.73
Enterprise Value/Ebitda30.70
Forecast
1Y Price Target
$257.44Price Target Upside14.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)5.36
Revenue Forecast (FY)$4.62B
Bulls Say, Bears Say
Bulls Say
Clinical Consumables GrowthStrong clinical consumables growth indicates expanding adoption of sequencing in diagnostics and clinical trials, a potentially durable demand stream. Continued mid-teens growth and a rich pipeline of tests can support recurring consumables revenue as clinical workflows become more established.
Recurring Consumables BaseA growing high-throughput installed base strengthens Illumina’s recurring-revenue model because customers must purchase consumables to use deployed instruments. Rising utilization and NovaSeq X adoption can create durable pull-through revenue beyond the initial hardware sale.
Cash Generation And MarginsRobust operating and free cash flow, together with restored profitability, improves Illumina’s ability to fund innovation, service debt, and return capital without relying solely on external financing. The strong earnings-to-cash conversion also supports the quality of the recent recovery.
Bears Say
Research Market DeclinesWeakness in research and applied consumables creates a meaningful drag on revenue because these markets remain important sources of sequencing demand. Continued declines through 2026 could offset clinical growth, reduce instrument utilization, and make consolidated growth more dependent on a narrower customer segment.
Pricing And Cost HeadwindsPersistent input-cost and pricing pressure can limit margin expansion even as revenue grows. Tariffs, shipping costs, and lower transition pricing may reduce the economic benefit of NovaSeq X adoption, requiring continued operational discipline to preserve the company’s recently improved profitability.
China Trade UncertaintyRegulatory and trade uncertainty in China can disrupt customer access, sales execution, and instrument or consumables demand in an important geographic market. The absence of a determined impact does not remove the risk that policy developments could constrain growth or increase operating complexity.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $106.12 and its highest was $309.35 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $35.63B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 11, 2027 which is in 103 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 29, 2026. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.356 by $0.084.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.53.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.44 in its last earnings report, beating expectations of $1.356. Following the earnings report the stock price went down -18.641%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$257.44 (14.50% Upside)
$257.44 (14.50% Upside)
Blogger Sentiment
Neutral
ILMN Sentiment 57%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 244.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $436.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Bullish
Bullish news 64%
Bearish news 36%
Bearish news 36%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.34%
12-Months-Change
Fundamentals
Return on Equity
31.45%
Trailing 12-Months
Asset Growth
10.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Illumina reported revenue, margin, EPS, cash flow, clinical demand, and NovaSeq X placements above expectations, raised full-year guidance, and highlighted expanding opportunities in clinical sequencing, multi-omics, software, and AI-based data sets. The main challenges were declines in research and applied markets, weaker instrument revenue in certain regions, ongoing pricing and cost headwinds, slower clinical conversion to the NovaSeq X, and uncertainty related to China and trade restrictions.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$257.44
▲(14.50% Upside)
Technical Analysis
Ownership Overview
0.78% Insiders
31.48% Mutual Funds
3.62% Other Institutional Investors
38.10% Public Companies and
Individual Investors